NCT00277862View on ClinicalTrials.gov

Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4

PHASE4CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

March 31, 2007

Study Completion Date

April 30, 2007

Conditions
Hepatitis C
Interventions
DRUG

Pegylated IFN- alpha 2b

DRUG

Ribavirin

Trial Locations (4)

11351,

AUS Specialized Hospital,, Cairo

Unknown

DIACSERA, Cairo

MISR Welding, Cairo

ELectricity Auth, Mynia and Cairo

Sponsors

Collaborators (1)

Schering-Plough
All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

collaborator

Fulbright

OTHER

collaborator

Tempus AI

INDUSTRY

collaborator

International Society for Infectious Diseases

OTHER

lead

Ain Shams University

OTHER

NCT00277862 - Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4 | Biotech Hunter | Biotech Hunter